These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35961838)

  • 1. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
    Chen CX; Hay JW
    Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
    Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
    Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.
    Guzauskas GF; Garbett S; Zhou Z; Schildcrout JS; Graves JA; Williams MS; Hao J; Jones LK; Spencer SJ; Jiang S; Veenstra DL; Peterson JF
    Ann Intern Med; 2023 May; 176(5):585-595. PubMed ID: 37155986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
    Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
    JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.
    Guzauskas GF; Jiang S; Garbett S; Zhou Z; Spencer SJ; Snyder SR; Graves JA; Williams MS; Hao J; Peterson JF; Veenstra DL
    Genet Med; 2022 May; 24(5):1017-1026. PubMed ID: 35227606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
    Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
    J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
    Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Hendy LE; Spees LP; Tak C; Carpenter DM; Thomas KC; Roberts MC
    Atherosclerosis; 2024 Jun; 393():117541. PubMed ID: 38677159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
    Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
    Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.